Angiodynamics (ANGO) reported $320M in revenue for fiscal 2025, +9.5% year on year. That ranks #2450 by revenue among 2853 SEC filers and #244 in Healthcare. It posted a net loss of −$36.7M for the same year. Revenue has declined 1.0% a year on average since 2015 ($354M then). The fiscal 2025 balance sheet shows $270M in total assets, $41.6M in cash and $49.8M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $320M | +9.5% | FY20252026-05-31 |
| Gross profitGrossProfit | $175M | +10.9% | FY20252026-05-31 |
| Operating incomeOperatingIncomeLoss | −$39.9M | +$27,000 | FY20252026-05-31 |
| Net incomeNetIncomeLoss | −$36.7M | −$2.7M | FY20252026-05-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $3.1M | +$13.2M | FY20252026-05-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.6M | −42.2% | FY20252026-05-31 |
| Total assetsAssets | $270M | −7.5% | FY20252025-11-30 |
| Shareholders' equityStockholdersEquity | $176M | −5.6% | FY20252025-11-30 |
| CashCashAndCashEquivalentsAtCarryingValue | $41.6M | −23.0% | FY20252025-11-30 |
| Long-term debtLongTermDebt | $49.8M | −64.2% | FY20222022-11-30 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-02-28 | $78.4M | −$8.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Angiodynamics Inc
- Ticker
- ANGO
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 05-31
- CIK
- 0001275187
Filings
- 10-KJul 14, 2026Open filing →
- 10-QApr 2, 2026Open filing →
- 10-QJan 6, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Tactile Systems TechnologyTCMD | $330M | $19.1M |
| Fulgent GeneticsFLGT | $323M | −$60.5M |
| DocgoDCGO | $322M | −$196M |
| AngiodynamicsANGO | $320M | −$36.7M |
| CormedixCRMD | $312M | $163M |
| Procept BioroboticsPRCT | $308M | −$95,572 |
| BilliontooneBLLN | $305M | $7.5M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Angiodynamics — Key figures |url=https://companiesranked.com/en/company/angiodynamics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Angiodynamics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/angiodynamicsBibTeX
@misc{companiesranked-en-company-angiodynamics-2026,
author = {{CompaniesRanked}},
title = {{Angiodynamics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/angiodynamics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-048138 · July 14, 2026
{{cite web |title=Angiodynamics — Key figures — 10-K (0001628280-26-048138) |url=https://www.sec.gov/Archives/edgar/data/1275187/000162828026048138/ango-20260531.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-07-14}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.